Breaking News, Promotions & Moves

I-Mab Names Permanent CEO

Dr. Sean Fu has over 20 years of industry experience in the life sciences industry, leading and developing clinical-stage assets.

Author Image

By: Charlie Sternberg

Associate Editor

I-Mab, a U.S.-based, global biotech company focused on the development of highly differentiated immunotherapies for the treatment of cancer, has appointed Sean (Xi-Yong) Fu, PhD, MBA as its permanent Chief Executive Officer (CEO) effective November 1, 2024.   Fu has served as Interim CEO since July 15, 2024. He will continue to serve as a member of the Board of Directors of I-Mab.   “Sean’s appointment serves as a significant step towards further realizing I-Mab’s mission o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters